The ongoing phase Ib clinical trial DESTINY-Lung03 is investigating the safety and efficacy of T-DXd in combination with immunotherapy for patients with HER2-positive advanced NSCLC. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.